Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Shares Shorted: Short Interest Down 80.8% in September

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 1,012 shares, a drop of 80.8% from the September 15th total of 5,259 shares. Based on an average trading volume of 31,252 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Institutional Investors Weigh In On Cardio Diagnostics

A hedge fund recently bought a new position in Cardio Diagnostics stock. Renaissance Technologies LLC purchased a new position in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned about 0.52% of Cardio Diagnostics at the end of the most recent reporting period. 8.06% of the stock is owned by hedge funds and other institutional investors.

Cardio Diagnostics Stock Up 0.5%

Shares of NASDAQ CDIO traded up $0.01 during trading on Friday, hitting $1.87. 16,359 shares of the company traded hands, compared to its average volume of 32,404. Cardio Diagnostics has a 1 year low of $0.97 and a 1 year high of $7.91. The company has a 50-day moving average price of $1.92 and a 200-day moving average price of $1.89. The firm has a market capitalization of $5.54 million, a P/E ratio of -0.64 and a beta of 2.29.

Cardio Diagnostics (NASDAQ:CDIO) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $0.01 million for the quarter. Cardio Diagnostics had a negative return on equity of 82.28% and a negative net margin of 43,133.33%.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cardio Diagnostics in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Cardio Diagnostics presently has an average rating of “Sell”.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc is a biotechnology company focused on developing precision medicine solutions for the prevention, detection and management of cardiovascular disease. The company combines genetic, epigenetic and clinical data with artificial intelligence to create blood-based tools designed to help identify an individual’s risk of coronary heart disease and support personalized care.

Its product portfolio has included Epi+Gen CHD, a blood-based test intended to assess a person’s susceptibility to coronary heart disease and provide information that may support preventive interventions.